Stocks in play: Small Pharma Inc.

Announces that SPL026, intravenous N,N-Dimethyltryptamine, with supportive therapy for the treatment of Major Depressive Disorder met the primary endpoint in its Phase IIa clinical trial, demonstrating a statistically significant and clinically relevant reduction in depressive symptoms at two-weeks post-dose, as compared to placebo. Further analysis of key secondary endpoints demonstrated a rapid and durable antidepressant effect to 12-weeks. Small Pharma Inc. shares V.DMT are trading unchanged at $0.10.

Read:

• Addressing the USA’s 200 to 1 Security Protection Gap is a Serious Concern for Tech Companies

• Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector

• Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio

• Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

• New Biotech Sector Drug Combinations Target a Drop in Pancreatic Cancer Mortality Rates